TP53 and breast carcinoma: To demonstrate regulation of DLL4 expression by DNA methylation, two LFS cell lines, a TP53 mutation carrier (3335) and a non-carrier (2852) of the cancer-prone family under study, breast cancer line (MCF7) and a normal control (HS27) were treated with 5′-aza-dC for 4 days.